Hims & Hers Health, Inc. (HIMS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Hims & Hers Health, Inc. operates a consumer-first digital health platform providing access to licensed healthcare professionals, telehealth consultations, and pharmacy fulfillment for conditions including sexual health, dermatology, mental health, and weight loss. The company operates as a single reporting unit.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $401.6 million | $226.7 million | $995.4 million | $625.4 million |
| Gross Profit | $317.9 million | $187.3 million | $803.6 million | $510.9 million |
| Gross Margin | 79% | 83% | 81% | 82% |
| Net Income (Loss) | $75.6 million | ($7.6 million) | $100.0 million | ($24.8 million) |
| Diluted EPS | $0.32 | ($0.04) | $0.43 | ($0.12) |
| Operating Cash Flow (9M) | $164.7 million | |||
| Free Cash Flow (9M) | $138.8 million | |||
| Cash & Investments (Sept 30, 2024) | $254.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 77% year-over-year in Q3 2024, driven by a 79% increase in Online Revenue and a 28% increase in Wholesale Revenue. Growth was fueled by new offerings launched after Q3 2023, particularly in weight loss.
- Profitability: The company reported a net income of $75.6 million in Q3 2024, a significant turnaround from a net loss of $7.6 million in the prior year. This was primarily due to a one-time income tax benefit of $60.8 million from the release of a valuation allowance on domestic deferred tax assets.
- Operating Expenses: Marketing expenses rose 57% to $182.3 million, reflecting increased investment in customer acquisition. Total operating expenses increased 51% to $295.5 million.
- Key Metrics: Subscribers grew 44% to 2.05 million. Average Order Value (AOV) increased 48% to $147, and Monthly Online Revenue per Average Subscriber rose 24% to $67.
- Acquisition: In September 2024, the company acquired MedisourceRx, a 503B compounding outsourcing facility, for approximately $31.0 million (cash and stock) to expand compounding capabilities.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue investing in manufacturing, fulfillment, and marketing to drive long-term growth. The company believes current cash resources are sufficient to support operations for the next 12 months.
- Share Repurchases: The company completed its $50 million 2023 repurchase program and initiated a new $100 million program in July 2024. As of September 30, $30 million had been repurchased under the new program, with $70 million remaining.
- Risks:
- Regulatory: Significant risks exist regarding FDA regulations on compounded GLP-1s (e.g., semaglutide), including potential shortages and evolving enforcement actions.
- Competition: The telehealth and weight loss markets are highly competitive, with potential for price pressure and new entrants.
- Supply Chain: Reliance on third-party manufacturers and pharmacies creates vulnerability to supply disruptions.
- Marketing: Changes in privacy laws or advertising platform policies could increase customer acquisition costs.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the sustainability of profitability without the one-time $60.8 million tax benefit from the valuation allowance release.
- GLP-1 Supply Chain: Monitor FDA shortage lists and regulatory actions regarding compounded semaglutide, a key growth driver.
- Customer Acquisition Costs (CAC): Assess the efficiency of the 57% increase in marketing spend relative to subscriber growth and retention rates.
- MedisourceRx Integration: Track the integration progress and revenue contribution of the newly acquired compounding facility.
- Share Repurchase Impact: Evaluate the impact of ongoing share repurchases on liquidity and capital allocation priorities.